Infliximab cost-effectiveness/safety?
Rothschild
B M
BM
D000911:Antibodies, Monoclonal / Q000191:economics*; D018501:Antirheumatic Agents / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab